See the DrugPatentWatch profile for ozempic

Ozempic (generic name: semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist, used primarily for the treatment of type 2 diabetes. It works by mimicking the functions of natural GLP-1 hormones in the body, which are involved in regulating blood glucose levels [1].

Ozempic's primary mechanism for regulating glucose involves enhancing insulin production. It does this in two main ways:

1. **Insulin secretion:** Ozempic stimulates the pancreas to produce and release insulin, a hormone that helps cells absorb glucose from the bloodstream [1]. This increased insulin secretion helps lower blood glucose levels, particularly after meals.

2. **Insulin sensitivity:** By slowing down gastric emptying, Ozempic helps to reduce the postprandial spike in blood glucose levels. This slower digestion allows the insulin released to have a more gradual and sustained effect on glucose regulation [1].

Moreover, Ozempic also decreases glucagon secretion, a hormone that increases blood glucose levels. By decreasing glucagon secretion, Ozempic further contributes to the regulation of blood glucose levels [1].

In summary, Ozempic affects insulin production by stimulating the pancreas to release insulin and slowing down gastric emptying, thereby enhancing insulin sensitivity. Additionally, it decreases glucagon secretion, which helps to regulate blood glucose levels.

Sources:
[1] DrugPatentWatch.com. (n.d.). Ozempic (semaglutide) - DrugPatentWatch. Retrieved from https://www.drugpatentwatch.com/drugs/ozempic